Compact, all-in-one mass photometer helps researchers verify sample quality before proceeding to cryo-EM, native MS, BLI, SPR, and other costly experiments OXFORD, United Kingdom, March 18, 2026 (GLOBE NEWSWIRE) — Refeyn, developer of pioneering mass photometry technology, announces the launch of MyMass™ mass photometer (MyMassMP), a compact instrument designed to
Akur8 Enters Life and Annuity Insurance Market with Strategic Acquisition of Slope Software Akur8, the leading Global Actuarial AI platform, announced today it has acquired Slope Software, a cloud-native, all-in-one actuarial modeling platform for life insurers and pension firms. PARIS and ATLANTA, March 17, 2026 (GLOBE NEWSWIRE) — Akur8, the
SAN FRANCISCO, March 17, 2026 (GLOBE NEWSWIRE) — Meltwater, a global leader in media, social, and consumer intelligence, announced Antony Cousins, VP of Product, has been named to PRWeek’s AI Top 25 list for 2026. The annual list spotlights the biggest communications technology players advancing artificial intelligence across the PR
Skild AI is partnering with ABB Robotics and Universal Robots to deploy its omni-bodied robot brain across industries and applications, from factory floors to collaborative systems, without task-by-task reprogramming PITTSBURGH, March 16, 2026 (GLOBE NEWSWIRE) — Skild AI, a pioneer in building generalized robot intelligence for any embodiment, today announced
Validation Confirms Science-Grade Integrity of the EarthDaily Constellation Perth captured by EDC-01 VANCOUVER, British Columbia and NEW YORK, March 12, 2026 (GLOBE NEWSWIRE) — EarthDaily today announced that its data products have achieved CEOS Analysis Ready Data (CEOS-ARD) compliance, a globally recognized standard established by the Committee on Earth Observation
EggNest™ Enhanced Radiation Protection System Announces CRT 2026 Clinical Data Superior Radiation Shielding in the Interventional Suite: The EggNest™ system (pictured) reduces scatter radiation exposure for the entire clinical team compared to the current standard of care. New clinical data presented as a Late-Breaking Trial at CRT 2026 confirms that
